CClinicalTrials.gg
CompletedNCT04746781Updated May 22, 2023

The Effect of 360 Video and MAPS on Enrollment in the DPP

An interventional study of Mobile 360° Video intervention and Motivation and Problem Solving (MAPS) in Diabetes Mellitus, Type 2 and PreDiabetes, sponsored by University of Utah. Completed at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2023-05-22.

Sponsored by University of Utah · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
818
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Study summary

We will conduct a three-armed randomized, clinical trial to test the incremental effectiveness of Mobile 360° Video and Motivation and Problem Solving in motivating individuals with Prediabetes to enroll in the Diabetes Prevention Program. all participants will receive notification that they have Prediabetes and education about Prediabetes, Type 2 diabetes, and the Diabetes Prevention Program, some participants will receive the additional interventions

Read the detailed description

More than 88 million Americans are at risk of developing Type 2 diabetes mellitus (T2DM). The one-year Diabetes Prevention Program (DPP) has been shown to be effective in reducing the risk of progressing from prediabetes to T2DM. However, most individuals who could benefit from the program never enroll.

Prior research has elucidated several reasons people do not enroll in the DPP. First, many people are not aware that they are at risk of developing T2DM, or that an efficacious program like the DPP exists. Second, the complications from T2DM are abstract, distal and difficult to imagine, which in turn leads to low motivation for risk-reducing behaviors. Finally, practical barriers limit DPP enrollment including cost, travel time, and scheduling. Prior research has tested rational appeals (such as provider-based education and referral) to enroll individuals in the DPP, with limited efficacy. In this project we will compare the effects of notification and education alone, notification and education plus mobile phone delivered videos (emotional appeal), and notification and education plus phone-based coaching utilizing a motivation and problem-solving approach. Our primary outcome will be enrollment and 1-month engagement in the DPP.

This three-armed randomized, clinical trial will be conducted within 2 health systems. Following an opt-out procedure offered to all eligible participants, participants will complete informed consent and a baseline survey. In the risk notification/education arm, we will send all participants a short message service (SMS) message with a link to a website that educates the public about their risk for developing T2DM and about the availability and efficacy of the DPP to address their risk. In the Mobile 360° Video intervention arm, after risk notification/education, participants will receive links to two 3-minute immersive Mobile 360° Videos (in which the viewer moves their phone to 'look around' the world of the video) on their smart phones. These videos are intended to influence affective and experiential perceptions of risk. The first video tells an emotional story of the negative effects on an individual's health and family life as they progress from prediabetes to T2DM and develop cardiovascular complications. The second video provides the viewer with a vicarious experience of the changes in vision that occur as diabetic retinopathy develops and worsens.

In the Motivation and Problem Solving (MAPS) arm, after risk notification/education, participants will be called by a health coach trained in counseling/coaching. The coach will guide them in setting health related goals and addressing any practical barriers to enrolling/engaging in the DPP, if that is consistent with their health goals.

02

Conditions studied

  • Diabetes Mellitus, Type 2
  • PreDiabetes
03

In context

Diabetes Mellitus, Type 2

9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

This study's enrollment of 818 is above the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

University of Utah is the lead sponsor of 969 studies on the registry; 178 are open to participants now.

Of its 107 completed or terminated interventional studies of FDA-regulated products, 62 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Are aged 18-89
  • Have a diagnosis of prediabetes within the past 5 years (ICD-10 code R73.03)
  • Have an email and mobile telephone number on record with the Health-system
  • Primary language of either English or Spanish

Exclusion criteria

Exclusion Criteria:

  • Type 2 diabetes mellitus (ICD-10-CM E11);
  • Type 1 diabetes mellitus (ICD-10-CM Diagnosis E10),
  • Diabetes mellitus due to underlying condition (ICD-10 E08);
  • Drug or chemical induced diabetes mellitus (ICD-10 E09);
  • Gestational diabetes (ICD-10 024.4);
  • Neonatal diabetes mellitus (ICD-10 P70.2);
  • Post-pancreatectomy diabetes mellitus (ICD-10 E13).
  • Patients whose primary language is other than Spanish or English will be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
818 participants (actual)

Study arms

  • Active comparator
    Risk notification/education arm

    We will send all participants a short message service (SMS) message with a link to a website that educates the public about their risk for developing T2DM and about the availability and efficacy of the DPP to address their risk

    Behavioral: Risk notification/education

  • Experimental
    Mobile 360° Video intervention arm

    After risk notification and education, participants will receive links to two 3-minute immersive Mobile 360° Videos (in which the viewer moves their phone to 'look around' the world of the video) on their smart phones. These videos are intended to influence affective and experiential perceptions of risk. The first video tells an emotional story of the negative effects on an individual's health and family life as they progress from prediabetes to T2DM and develop cardiovascular complications. The second video provides the viewer with a vicarious experience of the changes in vision that occur as diabetic retinopathy develops and worsens.

    Behavioral: Mobile 360° Video intervention · Behavioral: Risk notification/education

  • Experimental
    Motivation and Problem Solving (MAPS) arm

    After risk notification and education, participants will be called by a health coach trained in counseling/coaching. The coach will guide them in setting goals related to their health, and addressing any practical barriers to enrolling/engaging in the DPP if that is consistent with their health goals. Per their preference, participants will receive up to 5 phone calls from the health coach over a 4 week period.

    Behavioral: Motivation and Problem Solving (MAPS) · Behavioral: Risk notification/education

Interventions

  • BehavioralMobile 360° Video intervention

    Using 360° Videos to educate participants about the effect of diabetes.

  • BehavioralMotivation and Problem Solving (MAPS)

    Using Motivation and Problem Solving to help people enroll in the Diabetes Prevention Program.

  • BehavioralRisk notification/education

    Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.

06

What researchers measure

Primary outcomes

  1. Diabetes prevention program enrollment

    Enrollment in the Diabetes prevention program . This data that is recorded by all Diabetes prevention programs and is required to be reported to the Centers for disease control. For individuals attending an in person-class. It is defined by the CDC as registration for the program. For individuals who enroll in an online DPP it is defined by the CDC as an individual setting their password for the app. For the purposes of this trial any individual meeting either of these criteria will be considered to have enrolled in the DPP.

    Time frame: 1-month

  2. 4 weeks of engagement in the Diabetes prevention program

    1-month engagement in the Diabetes prevention program. This is data that is recorded by all Diabetes prevention programs and is required to be reported to the Centers for Disease Control. For individuals attending an in person-class, it is defined by the CDC as the individual attending at least 2 of the first four sessions. For individuals who enroll in an online DPP it is defined by the CDC as completing at least two of the following activities: (A) Complete two education modules (B) Send at least 1 In-App message and/or Group Wall post (C) Set or log at least one behavior (D) Log, plan or research at least three meals (E) Log physical activity at least three (F) Weigh-in on three or more days in two out of the first four weeks For the purposes of this trial any individual meeting either of these criteria will be considered to have engaged in the DPP for the first month.

    Time frame: 1 month

Secondary outcomes

  1. Changes in self-efficacy

    Self-efficacy related to Diabetes prevention program participation as well as diet, exercise, and weight loss will be measured using the brief (16 items) Self-Efficacy scales adapted from Wilson 2016: Wilson KE, Harden SM, Almeida FA, et al. Brief self-efficacy scales for use in weight-loss trials: Preliminary evidence of validity. Psychological assessment 2016; 28(10): 1255-64. This will be measured pre and post intervention and the change score calculated and compared across intervention arms

    Time frame: 1 month

  2. Changes in Risk perceptions

    Risk perceptions related to development of Type 2 Diabetes will be measured using an 18-item measure of risk perceptions for Type 2 diabetes developed by Ferrer et al: Ferrer RA, Klein WMP, Persoskie A, Avishai-Yitshak A, Sheeran P. The Tripartite Model of Risk Perception (TRIRISK): Distinguishing Deliberative, Affective, and Experiential Components of Perceived Risk. Annals of Behavioral Medicine 2016; 50(5): 653-63. This measure includes 6 items each to measure three different aspects of risk perception: deliberative, affective and experiential risk perceptions. we will calculate the sub scores for these dimensions and compare changes in them across intervention arms

    Time frame: 1 month

07

Study locations

1 site
  • University of Utah
    Salt Lake City, Utah 84108, United States
08

References and documents

Publications

  • Gibson B, Simonsen S, Barton J, Zhang Y, Altizer R, Lundberg K, Wetter DW. Motivation and Problem Solving Versus Mobile 360 degrees Videos to Promote Enrollment in the National Diabetes Prevention Program's Lifestyle Change Program Among People With Prediabetes: Protocol for a Randomized Trial. JMIR Res Protoc. 2021 Jun 14;10(6):e28884. doi: 10.2196/28884. PubMed 34125075 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04746781
Lead sponsor
University of Utah
Collaborators
Centers for Disease Control and Prevention
Responsible party
Bryan Smith Gibson (Assistant Professor Biomedical Informatics, University of Utah) — Principal investigator
First posted
Feb 10, 2021
Start date
Feb 17, 2021
Primary completion
Dec 15, 2022
Completion
Dec 15, 2022
Last update
May 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion